Driving cars to the clinic for solid tumors
FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several decades of technology development and interrogation of the properties of these gene therapies. CART cells exist as personalized “living drugs” and have demonstrated astounding anti-tumor efficacy in patients...
Gespeichert in:
| Veröffentlicht in: | Gene therapy 2018-06, Vol.25 (3), p.165-175 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 175 |
|---|---|
| container_issue | 3 |
| container_start_page | 165 |
| container_title | Gene therapy |
| container_volume | 25 |
| creator | Castellarin, Mauro Watanabe, Keisuke June, Carl H. Kloss, Christopher C. Posey, Avery D. |
| description | FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several decades of technology development and interrogation of the properties of these gene therapies. CART cells exist as personalized “living drugs” and have demonstrated astounding anti-tumor efficacy in patients with leukemia and lymphoma. However, the future promise of CART efficacy for solid tumors, the greatest unmet burden, is met with a number of challenges that must be surmounted for effective immune responses. In this review, we discuss the next-generation developments of CARs to target solid tumors, including fine-tuned and combinational-targeting receptors. We consider the structural intricacies of the CAR molecules that influence optimal signaling and CART survival, and review pre-clinical cell-intrinsic and cell-extrinsic combinational therapy approaches. |
| doi_str_mv | 10.1038/s41434-018-0007-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2052805804</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2052805804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-39573543c49e67cd9a0948efa50be898201eea6544338a1557ec97cab1cab433</originalsourceid><addsrcrecordid>eNp1kF1LwzAUhoMobk5_gDdS8EaQ6MlXm1zK_ISBN7sPWZbOjraZSSvz35vRqSB4EQLJ877n8CB0TuCGAJO3kRPOOAYiMQAUeHuAxoQXORY8p4doDCpXuCBUjtBJjOvE8ELSYzSiSkpQIMfo-j5UH1W7yqwJMet81r25zNZVW9ms9CGLvq6WWdc3PsRTdFSaOrqz_T1B88eH-fQZz16fXqZ3M2y5JB1mShRMcGa5cnlhl8qA4tKVRsDCSSUpEOdMLjhnTBoiROGsKqxZkHTS2wRdDbWb4N97FzvdVNG6ujat833UFASVICTwhF7-Qde-D21aLlE5JQyY2hWSgbLBxxhcqTehakz41AT0TqQeROokUu9E6m3KXOyb-0Xjlj-Jb3MJoAMQ01e7cuF39P-tXzM0e7o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2062130393</pqid></control><display><type>article</type><title>Driving cars to the clinic for solid tumors</title><source>Springer Nature - Complete Springer Journals</source><creator>Castellarin, Mauro ; Watanabe, Keisuke ; June, Carl H. ; Kloss, Christopher C. ; Posey, Avery D.</creator><creatorcontrib>Castellarin, Mauro ; Watanabe, Keisuke ; June, Carl H. ; Kloss, Christopher C. ; Posey, Avery D.</creatorcontrib><description>FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several decades of technology development and interrogation of the properties of these gene therapies. CART cells exist as personalized “living drugs” and have demonstrated astounding anti-tumor efficacy in patients with leukemia and lymphoma. However, the future promise of CART efficacy for solid tumors, the greatest unmet burden, is met with a number of challenges that must be surmounted for effective immune responses. In this review, we discuss the next-generation developments of CARs to target solid tumors, including fine-tuned and combinational-targeting receptors. We consider the structural intricacies of the CAR molecules that influence optimal signaling and CART survival, and review pre-clinical cell-intrinsic and cell-extrinsic combinational therapy approaches.</description><identifier>ISSN: 0969-7128</identifier><identifier>EISSN: 1476-5462</identifier><identifier>DOI: 10.1038/s41434-018-0007-x</identifier><identifier>PMID: 29880908</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/251 ; 631/67/580 ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; Chimeric antigen receptors ; Comment ; FDA approval ; Gene Expression ; Gene Therapy ; Human Genetics ; Immunosuppressive agents ; Lymphocytes T ; Lymphoma ; Nanotechnology ; Solid tumors ; Tumors</subject><ispartof>Gene therapy, 2018-06, Vol.25 (3), p.165-175</ispartof><rights>The Author(s) 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-39573543c49e67cd9a0948efa50be898201eea6544338a1557ec97cab1cab433</citedby><cites>FETCH-LOGICAL-c481t-39573543c49e67cd9a0948efa50be898201eea6544338a1557ec97cab1cab433</cites><orcidid>0000-0003-0241-3557</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41434-018-0007-x$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41434-018-0007-x$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29880908$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Castellarin, Mauro</creatorcontrib><creatorcontrib>Watanabe, Keisuke</creatorcontrib><creatorcontrib>June, Carl H.</creatorcontrib><creatorcontrib>Kloss, Christopher C.</creatorcontrib><creatorcontrib>Posey, Avery D.</creatorcontrib><title>Driving cars to the clinic for solid tumors</title><title>Gene therapy</title><addtitle>Gene Ther</addtitle><addtitle>Gene Ther</addtitle><description>FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several decades of technology development and interrogation of the properties of these gene therapies. CART cells exist as personalized “living drugs” and have demonstrated astounding anti-tumor efficacy in patients with leukemia and lymphoma. However, the future promise of CART efficacy for solid tumors, the greatest unmet burden, is met with a number of challenges that must be surmounted for effective immune responses. In this review, we discuss the next-generation developments of CARs to target solid tumors, including fine-tuned and combinational-targeting receptors. We consider the structural intricacies of the CAR molecules that influence optimal signaling and CART survival, and review pre-clinical cell-intrinsic and cell-extrinsic combinational therapy approaches.</description><subject>631/250/251</subject><subject>631/67/580</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>Chimeric antigen receptors</subject><subject>Comment</subject><subject>FDA approval</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Human Genetics</subject><subject>Immunosuppressive agents</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Nanotechnology</subject><subject>Solid tumors</subject><subject>Tumors</subject><issn>0969-7128</issn><issn>1476-5462</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kF1LwzAUhoMobk5_gDdS8EaQ6MlXm1zK_ISBN7sPWZbOjraZSSvz35vRqSB4EQLJ877n8CB0TuCGAJO3kRPOOAYiMQAUeHuAxoQXORY8p4doDCpXuCBUjtBJjOvE8ELSYzSiSkpQIMfo-j5UH1W7yqwJMet81r25zNZVW9ms9CGLvq6WWdc3PsRTdFSaOrqz_T1B88eH-fQZz16fXqZ3M2y5JB1mShRMcGa5cnlhl8qA4tKVRsDCSSUpEOdMLjhnTBoiROGsKqxZkHTS2wRdDbWb4N97FzvdVNG6ujat833UFASVICTwhF7-Qde-D21aLlE5JQyY2hWSgbLBxxhcqTehakz41AT0TqQeROokUu9E6m3KXOyb-0Xjlj-Jb3MJoAMQ01e7cuF39P-tXzM0e7o</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Castellarin, Mauro</creator><creator>Watanabe, Keisuke</creator><creator>June, Carl H.</creator><creator>Kloss, Christopher C.</creator><creator>Posey, Avery D.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0241-3557</orcidid></search><sort><creationdate>20180601</creationdate><title>Driving cars to the clinic for solid tumors</title><author>Castellarin, Mauro ; Watanabe, Keisuke ; June, Carl H. ; Kloss, Christopher C. ; Posey, Avery D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-39573543c49e67cd9a0948efa50be898201eea6544338a1557ec97cab1cab433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>631/250/251</topic><topic>631/67/580</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>Chimeric antigen receptors</topic><topic>Comment</topic><topic>FDA approval</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Human Genetics</topic><topic>Immunosuppressive agents</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Nanotechnology</topic><topic>Solid tumors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castellarin, Mauro</creatorcontrib><creatorcontrib>Watanabe, Keisuke</creatorcontrib><creatorcontrib>June, Carl H.</creatorcontrib><creatorcontrib>Kloss, Christopher C.</creatorcontrib><creatorcontrib>Posey, Avery D.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castellarin, Mauro</au><au>Watanabe, Keisuke</au><au>June, Carl H.</au><au>Kloss, Christopher C.</au><au>Posey, Avery D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Driving cars to the clinic for solid tumors</atitle><jtitle>Gene therapy</jtitle><stitle>Gene Ther</stitle><addtitle>Gene Ther</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>25</volume><issue>3</issue><spage>165</spage><epage>175</epage><pages>165-175</pages><issn>0969-7128</issn><eissn>1476-5462</eissn><abstract>FDA approval of chimeric antigen receptor T cells (CART cells) is the culmination of several decades of technology development and interrogation of the properties of these gene therapies. CART cells exist as personalized “living drugs” and have demonstrated astounding anti-tumor efficacy in patients with leukemia and lymphoma. However, the future promise of CART efficacy for solid tumors, the greatest unmet burden, is met with a number of challenges that must be surmounted for effective immune responses. In this review, we discuss the next-generation developments of CARs to target solid tumors, including fine-tuned and combinational-targeting receptors. We consider the structural intricacies of the CAR molecules that influence optimal signaling and CART survival, and review pre-clinical cell-intrinsic and cell-extrinsic combinational therapy approaches.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>29880908</pmid><doi>10.1038/s41434-018-0007-x</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0241-3557</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-7128 |
| ispartof | Gene therapy, 2018-06, Vol.25 (3), p.165-175 |
| issn | 0969-7128 1476-5462 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2052805804 |
| source | Springer Nature - Complete Springer Journals |
| subjects | 631/250/251 631/67/580 Biomedical and Life Sciences Biomedicine Cell Biology Chimeric antigen receptors Comment FDA approval Gene Expression Gene Therapy Human Genetics Immunosuppressive agents Lymphocytes T Lymphoma Nanotechnology Solid tumors Tumors |
| title | Driving cars to the clinic for solid tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A15%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Driving%20cars%20to%20the%20clinic%20for%20solid%20tumors&rft.jtitle=Gene%20therapy&rft.au=Castellarin,%20Mauro&rft.date=2018-06-01&rft.volume=25&rft.issue=3&rft.spage=165&rft.epage=175&rft.pages=165-175&rft.issn=0969-7128&rft.eissn=1476-5462&rft_id=info:doi/10.1038/s41434-018-0007-x&rft_dat=%3Cproquest_cross%3E2052805804%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2062130393&rft_id=info:pmid/29880908&rfr_iscdi=true |